Gene editing makes "ready-to-use" CAR-T therapy Phase 1 clinical trial results are positive

Today, CRISPR Therapeutics announced that the allogeneic CAR-T cell therapy CTX110, modified by CRISPR gene editing technology, has obtained positive safety and efficacy results in a phase 1 clinical trial for the treatment of CD19-positive B-cell cancers

CTX110 is an allogeneic CAR-T cell therapy manufactured using CRISPR gene editing technology

▲Introduction of CTX110 (picture source: CRISPR Therapeutics)

In this clinical trial, a total of 26 large B-cell lymphoma patients received CTX110 treatment and were followed up for at least 28 days

▲Efficacy data of phase 1 clinical trial of CTX110 (picture source: reference [1])

After 6 months of treatment, the complete remission rate was 21%, and the longest remission lasted more than 18 months, showing the potential of CTX110 to bring sustained remission

In terms of safety, CTX110 shows differentiated positive safety features

Only one patient with HHV-6 encephalitis developed immune effector cell-related neurotoxicity syndrome (ICANS) above grade 3

Picture source: reference [1]

Reference materials:

[1] CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies.

(The original text has been deleted)